Counsyl today announced the appointment of Pamela Sedmak, former president and chief executive officer of Aetna Medicaid/Dual Eligibles and current senior advisor at McKinsey & Company, to the company’s board of directors.
“We’re thrilled to have Pamela join our board and are confident in the valuable contributions she will make to Counsyl going forward,” said Ramji Srinivasan, co-founder and chief executive officer of Counsyl. “Pamela understands patient, provider and payer needs through her extensive experience working with some of the largest domestic payer organizations. Her insights and perspective will be essential for Counsyl in achieving our mission to provide actionable information that guides women and their families in making critical and timely health decisions.”
Pamela is a senior advisor at McKinsey & Company, a worldwide management consulting firm. Prior to this role, she served as president and chief executive officer at Aetna Medicaid/Dual Eligibles, a multi-billion dollar business segment with 3 million members in 17 states. Pamela also previously served as senior vice president and chief financial, strategy and innovation officer at Blue Cross Blue Shield of Minnesota and chief financial officer and chief operating officer at CareSource. Her career began at General Electric, holding general management and financial executive roles. In addition, Pamela has served on the boards of the Make-A-Wish Foundation in Minnesota, Arizona Chamber of Commerce and Anderson Alumni Council at the University of New Mexico Anderson School of Management. She has a bachelor’s degree in finance from the University of New Mexico and a master’s degree from Case Western Reserve University. Pamela was inducted into the Hall of Fame by the University of New Mexico’s Anderson School of Management.
“I’m honored to join Counsyl’s board and thrilled to provide critical insights to the company’s core business priorities, particularly as they relate to market access and reimbursement,” said Pamela Sedmak. “Through my experience, I am able to help Counsyl navigate the complex payer environment and how the company can continue to demonstrate the clinical value of Counsyl’s industry-leading genetic screening products.”
Since the company’s founding in 2007, Counsyl has championed advances in genetic screening for women and their families and has screened more than 850,000 patients, served more than 17,000 health care providers and provided more than 60,000 genetic counseling sessions.
Counsyl’s suite of products includes:
Counsyl Foresight™ Carrier Screen: Identifies carrier status of couples to determine risk of hereditary conditions.
Counsyl Prelude™ Prenatal Screen: As early as the tenth week of pregnancy, this non-invasive screening detects a fetus’ risk for chromosomal conditions such as Down syndrome.
Counsyl Reliant™ Cancer Screen: Analyzes genes associated with an increased risk of 10 common cancers, including breast, ovarian and pancreatic cancer.
Counsyl Complete™: Our complete practice workflow solution, including pre-test education, billing support, clear results reporting and on-demand genetic counseling.